Search

Your search keyword '"Fujishima, Yoshimi"' showing total 31 results
Start Over Author "Fujishima, Yoshimi"
31 results on '"Fujishima, Yoshimi"'

1. Current Roles of Ramucirumab in the Sequential Treatment of Unresectable Hepatocellular Carcinoma

Author

KOIZUMI, AKIRA, primary, KOMATSU, SHOHEI, additional, OMIYA, SATOSHI, additional, YANO, YOSHIHIKO, additional, FUJISHIMA, YOSHIMI, additional, ISHIDA, JUN, additional, KIDO, MASAHIRO, additional, GON, HIDETOSHI, additional, FUKUSHIMA, KENJI, additional, URADE, TAKESHI, additional, SO, SHINICHI, additional, YOSHIDA, TOSHIHIKO, additional, ARAI, KEISUKE, additional, FUJINAKA, RYOSUKE, additional, SHIMURA, YUHI, additional, YANAGIMOTO, HIROAKI, additional, TOYAMA, HIROCHIKA, additional, UEDA, YOSHIHIDE, additional, KODAMA, YUZO, additional, and FUKUMOTO, TAKUMI, additional

Published
2024
Full Text
View/download PDF

3. Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma.

Author

Ishihara, Nobuaki, Komatsu, Shohei, Sofue, Keitaro, Ueshima, Eisuke, Yano, Yoshihiko, Fujishima, Yoshimi, Ishida, Jun, Kido, Masahiro, Gon, Hidetoshi, Fukushima, Kenji, Urade, Takeshi, Yanagimoto, Hiroaki, Toyama, Hirochika, Ueda, Yoshihide, Kodama, Yuzo, Murakami, Takamichi, and Fukumoto, Takumi

Subjects
CONVERSION therapy, HEPATOCELLULAR carcinoma, TUMOR treatment, TREATMENT effectiveness, ATEZOLIZUMAB
Abstract

Aim: The IMbrave150 trial revealed that atezolizumab plus bevacizumab (AtezoBv) showed a higher objective response rate (ORR) in patients with advanced hepatocellular carcinoma (HCC). Although conversion therapy after AtezoBv has been recently reported, markers predictive of its efficacy, particularly radiological imaging markers, have not yet been identified. The present study focused on tumor morphological appearance on radiological imaging and evaluated whether it could be associated with AtezoBv efficacy. Methods: Ninety‐five intrahepatic lesions in 74 patients who were given AtezoBv for advanced HCC were recruited for evaluation. The lesions were divided into two groups, simple nodular (SN group) and non‐simple nodular (non‐SN group), based on the gross morphology on pretreatment imaging, and retrospectively evaluated for treatment response and other relevant clinical outcomes. Results: Assessing the size of individual tumors after treatment, waterfall plots showed that tumor shrinkage in the non‐SN group including 56 lesions was higher than that in the SN group comprising 39 lesions. The ORR was significantly higher in the non‐SN group (39.3% vs. 15.4%, p = 0.012). Additionally, the median time to nodular progression was longer in the non‐SN group (21.0 months vs. 8.1 months, p = 0.119) compared to the SN group. Six patients with non‐SN lesions underwent sequential local therapy. Conclusions: Atezolizumab plus bevacizumab may show increased therapeutic efficacy in patients with tumors with a higher potential for aggressive oncological behavior, such as non‐SN lesions. Treatment strategies focusing on conversion therapy may be crucial in patients with non‐SN lesions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Device-related Mycobacterium mageritense Infection in a Patient Treated with Nivolumab for Metastatic Breast Cancer

Author

Koyama, Taiji, Funakoshi, Yohei, Imamura, Yoshinori, Nishimura, Sho, Fujishima, Yoshimi, Toyoda, Masanori, Kiyota, Naomi, Tanino, Hirokazu, and Minami, Hironobu

Subjects
nontuberculous mycobacteria, nivolumab, anti-PD-1 antibody, Antineoplastic Agents, Immunological, breast cancer, Mycobacterium mageritense, Programmed Cell Death 1 Receptor, Humans, Female, Case Report, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Mycobacteriaceae
Abstract

Treatment with anti-programmed cell death-1 (PD-1) antibodies improves the anti-cancer immune response and can provide a meaningful clinical benefit to cancer patients. However, this treatment can result in specific autoimmune toxicities, termed immune-related adverse events (irAEs). Although irAEs are well recognized, the development of infectious diseases due to this treatment is not often observed. Some recent reports have indicated that patients who receive anti-PD-1 antibodies are at a higher risk for tuberculosis than others. However, reports on nontuberculous mycobacterial infection during anti-PD-1 antibody treatment are still rare. We herein report the first case of Mycobacterium mageritense infection during anti-PD-1 antibody treatment.

Published
2021

7. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma

Author

KOMATSU, SHOHEI, primary, YANO, YOSHIHIKO, additional, FUJISHIMA, YOSHIMI, additional, ISHIDA, JUN, additional, KIDO, MASAHIRO, additional, KURAMITSU, KAORI, additional, YAMAMOTO, ATSUSHI, additional, GOTO, TADAHIRO, additional, YANAGIMOTO, HIROAKI, additional, TOYAMA, HIROCHIKA, additional, UEDA, YOSHIHIDE, additional, KODAMA, YUZO, additional, and FUKUMOTO, TAKUMI, additional

Published
2022
Full Text
View/download PDF

8. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma

Author

Komatsu, Shohei, primary, Yano, Yoshihiko, additional, Fujishima, Yoshimi, additional, Ishida, Jun, additional, Kido, Masahiro, additional, Kuramitsu, Kaori, additional, Yamamoto, Atsushi, additional, Goto, Tadahiro, additional, Yanagimoto, Hiroaki, additional, Toyama, Hirochika, additional, Ueda, Yoshihide, additional, Kodama, Yuzo, additional, and Fukumoto, Takumi, additional

Published
2021
Full Text
View/download PDF

9. Secondary CIC‑rearranged sarcoma responsive to chemotherapy regimens for Ewing sarcoma: A case report

Author

Kimbara, Shiro, primary, Imamura, Yoshinori, additional, Kiyota, Naomi, additional, Takakura, Hidetomo, additional, Matsumoto, Sakuya, additional, Koyama, Taiji, additional, Fujishima, Yoshimi, additional, Funakoshi, Yohei, additional, Toyoda, Masanori, additional, Hirose, Takanori, additional, Kanzawa, Maki, additional, Kawamoto, Teruya, additional, Hara, Hitomi, additional, and Minami, Hironobu, additional

Published
2021
Full Text
View/download PDF

12. Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial)

Author

Sai, Satoshi, primary, Toyoda, Masanori, additional, Tobimatsu, Kazutoshi, additional, Satake, Hironaga, additional, Yasui, Hisateru, additional, Kimbara, Shiro, additional, Koyama, Taiji, additional, Fujishima, Yoshimi, additional, Imamura, Yoshinori, additional, Funakoshi, Yohei, additional, Kiyota, Naomi, additional, Toyama, Hirochika, additional, Kodama, Yuzo, additional, and Minami, Hironobu, additional

Published
2020
Full Text
View/download PDF

14. Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal Growth Factor Receptor-Induced Acne-Like Rash: A Randomized Left-Right Comparative Evaluation (APPEARANCE)

Author

Chayahara, Naoko, primary, Mukohara, Toru, additional, Tachihara, Motoko, additional, Fujishima, Yoshimi, additional, Fukunaga, Atsushi, additional, Washio, Ken, additional, Yamamoto, Masatsugu, additional, Nakata, Kyosuke, additional, Kobayashi, Kazuyuki, additional, Takenaka, Kei, additional, Toyoda, Masanori, additional, Kiyota, Naomi, additional, Tobimatsu, Kazutoshi, additional, Doi, Hisayo, additional, Mizuta, Naomi, additional, Marugami, Naho, additional, Kawaguchi, Atsushi, additional, Nishigori, Chikako, additional, Nishimura, Yoshihiro, additional, and Minami, Hironobu, additional

Published
2019
Full Text
View/download PDF

15. Adapalene gel 0.1% vs. placebo as prophylaxis for anti-EGFR-induced acne-like rash: a randomized comparative evaluation

Author

Fujishima, Yoshimi, primary, Chayahara, Naoko, additional, Tachihara, Motoko, additional, Fukunaga, Atsushi, additional, Washio, Ken, additional, Yamamoto, Masatsugu, additional, Toyoda, Masanori, additional, Tobimatsu, Kazutoshi, additional, Doi, Hisayo, additional, Mizuta, Naomi, additional, Kawaguchi, Atsushi, additional, Nishigori, Chikako, additional, Nishimura, Yoshihiro, additional, Mukohara, Toru, additional, and Minami, Hironobu, additional

Published
2018
Full Text
View/download PDF

16. Adapalene gel 0.1% vs. placebo as prophylaxis for anti-EGFR-induced acne-like rash: A randomized left-right comparative evaluation (APPEARANCE).

Author

Tachihara, Motoko, primary, Chayahara, Naoko, additional, Fujishima, Yoshimi, additional, Fukunaga, Atsushi, additional, Washio, Ken, additional, Yamamoto, Masatsugu, additional, Nakata, Kyosuke, additional, Kobayashi, Kazuyuki, additional, Takenaka, Kei, additional, Toyoda, Masanori, additional, Kiyota, Naomi, additional, Tobimatsu, Kazutoshi, additional, Doi, Hisayo, additional, Mizuta, Naomi, additional, Marugami, Naho, additional, Kawaguchi, Atsushi, additional, Nishigori, Chikako, additional, Nishimura, Yoshihiro, additional, Mukohara, Toru, additional, and Minami, Hironobu, additional

Published
2018
Full Text
View/download PDF

20. Endoscopic Submucosal Dissection (ESD) with Additional Therapy for Superficial Esophageal Cancer with Submucosal Invasion

Author

Ikeda, Atsuki, primary, Hoshi, Namiko, additional, Yoshizaki, Tetsuya, additional, Fujishima, Yoshimi, additional, Ishida, Tsukasa, additional, Morita, Yoshinori, additional, Ejima, Yasuo, additional, Toyonaga, Takashi, additional, Kakechi, Yoshihiro, additional, Yokosaki, Hiroshi, additional, and Azuma, Takeshi, additional

Published
2015
Full Text
View/download PDF

25. AP1B plays an important role in intestinal tumorigenesis with the truncating mutation of an APC gene

Author

Mimura, Mitsuko, primary, Masuda, Atsuhiro, additional, Nishiumi, Shin, additional, Kawakami, Kazuyuki, additional, Fujishima, Yoshimi, additional, Yoshie, Tomoo, additional, Mizuno, Shigeto, additional, Miki, Ikuya, additional, Ohno, Hiroshi, additional, Hase, Koji, additional, Minamoto, Toshinari, additional, Azuma, Takeshi, additional, and Yoshida, Masaru, additional

Published
2011
Full Text
View/download PDF

27. Effects of Bolus Injection of 5-Fluorouracil on Steady-State Plasma Concentrations of 5-Fluorouracil in Japanese Patients with Advanced Colorectal Cancer

Author

Tamura, Takao, primary, Kuwahara, Akiko, additional, Kadoyama, Kaori, additional, Yamamori, Motohiro, additional, Nishiguchi, Kohshi, additional, Inokuma, Tsubasa, additional, Takemoto, Yoshiji, additional, Chayahara, Naoko, additional, Okuno, Tatsuya, additional, Miki, Ikuya, additional, Fujishima, Yoshimi, additional, and Sakaeda, Toshiyuki, additional

Published
2011
Full Text
View/download PDF

28. Regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report.

Author

Kimbara, Shiro, Imamura, Yoshinori, Yakushijin, Kimikazu, Higashime, Ako, Koyama, Taiji, Fujishima, Yoshimi, Funakoshi, Yohei, Toyoda, Masanori, Kiyota, Naomi, Matsuoka, Hiroshi, and Minami, Hironobu

Subjects
IDIOPATHIC thrombocytopenic purpura, PLATELET-derived growth factor receptors, CANCER remission, COLON cancer
Abstract

Regorafenib is an oral multi-kinase inhibitor which targets tumor angiogenesis, the tumor microenvironment and oncogenesis. Based on this mode of action, regorafenib has a broad spectrum of toxicities. However, at present, few reports have focused on autoimmune adverse events. We report a first case of regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission during treatment for the patients with heavily treated advanced colorectal cancer. This case report highlights the need for caution with regard to regorafenib treatment in patients with cancer with concomitant immune thrombocytopenic purpura. [ABSTRACT FROM AUTHOR]

Published
2021

29. Monoacetylcurcumin strongly regulates inflammatory responses through inhibition of NF-kappaB activation.

Author

Nishida M, Nishiumi S, Mizushina Y, Fujishima Y, Yamamoto K, Masuda A, Mizuno S, Fujita T, Morita Y, Kutsumi H, Yoshida H, Azuma T, and Yoshida M

Subjects
Animals, Anti-Inflammatory Agents chemistry, Anti-Inflammatory Agents therapeutic use, Cell Line, Curcumin chemistry, Curcumin metabolism, Curcumin therapeutic use, Humans, Inflammation chemically induced, Inflammation drug therapy, Lipopolysaccharides immunology, Lipopolysaccharides pharmacology, Macrophages drug effects, Macrophages metabolism, Male, Mice, Mice, Inbred C57BL, Reactive Oxygen Species metabolism, Tumor Necrosis Factor-alpha metabolism, Anti-Inflammatory Agents metabolism, Curcumin analogs & derivatives, Inflammation metabolism, NF-kappa B antagonists & inhibitors, NF-kappa B metabolism
Abstract

Curcumin, a component of turmeric (Curcuma longa), is known to exert a variety of biological functions including anti-inflammatory activity. We examined the inhibitory effects of chemically synthesized derivatives of curcumin against inflammatory responses and compared them with those of curcumin, in order to find derivatives with stronger effects than curcumin. In a cell culture system using the mouse macrophage cell line RAW264.7, monoacetylcurcumin strongly inhibited IkappaB phosphorylation, nuclear factor (NF)-kappaB activation and tumor necrosis factor (TNF)-alpha production induced by lipopolysaccharide (LPS). In addition, oral administration of monoacetylcurcumin to mice led to greater suppression of TNF-alpha production after LPS stimulation than the administration of curcumin or tetrahydrocurcumin in vivo. Monoacetylcurcumin also inhibited the LPS-induced NF-kappaB activation in the liver. Collectively, monoacetylcurcumin is a potential chemopreventive agent for treating inflammatory responses more effectively than curcumin.

Published
2010
Full Text
View/download PDF

30. [A case of advanced gastric cancer with disseminated carcinomatosis of bone marrow treated by S-1 and CDDP].

Author

Fujishima Y, Yoneda R, Iwai M, Fukunaga H, Miura M, Koide M, and Fukuda T

Subjects
Adult, Antimetabolites, Antineoplastic administration & dosage, Cisplatin administration & dosage, Drug Combinations, Humans, Male, Oxonic Acid administration & dosage, Quality of Life, Tegafur administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Neoplasms drug therapy, Bone Neoplasms secondary, Carcinoma drug therapy, Carcinoma secondary, Stomach Neoplasms pathology
Abstract

A 33-year-old man was admitted to our hospital due to DIC and multiple bone metastasis after distal gastrectomy for gastric cancer (Stage IIIB). We diagnosed disseminated carcinomatosis of bone marrow by gastric cancer. The patient was treated with combination chemotherapy of S-1 and CDDP (S-1 80 mg/m (2), po, day 1-21 and CDDP 60 mg/m(2), iv, day 8). After one course of the treatment, DIC was resolved and severe pain in his back and legs which had been poorly controlled was dramatically improved. He could thus be discharged from our hospital and survived for about six months. S-1 and CDDP therapy are considered to be effective for disseminated carcinomatosis of bone marrow due to gastric cancer, even if complicated by DIC.

Published
2009

31. [Intracellular traffic and the immune surveillance by neonatal Fcgamma receptor for IgG].

Author

Yoshida M, Masuda A, Fujishima Y, Nishiumi S, Mizuno S, Kutsumi H, Inokuchi H, and Azuma T

Subjects
Animals, Epithelial Cells metabolism, Female, Humans, Hydrogen-Ion Concentration, Immunoglobulin G physiology, Lymphocyte Activation, Maternal-Fetal Exchange, Mucous Membrane metabolism, Pregnancy, T-Lymphocytes immunology, Histocompatibility Antigens Class I physiology, Immunoglobulin G metabolism, Immunologic Surveillance, Receptors, Fc physiology
Published
2009

Catalog

Books, media, physical & digital resources
See catalog results